 |
8 Diseases |  |
0 Trials |
|
0 Trials |  |
81 News |  |
- | Oral Pyridorin (pyridoxamine) / NephroGenex
Preclinical, Journal: Lactose and Fructo-oligosaccharides Increase Visceral Sensitivity in Mice via Glycation Processes, Increasing Mast Cell Density in Colonic Mucosa. (Pubmed Central) - Apr 10, 2020
Lactose and/or pyridoxamine did not produce alterations in fecal microbiota of mice. Our findings indicate that preventing glycation reactions might reduce abdominal pain in patients with IBS with sensitivity to FODMAPs.
- | Oral Pyridorin (pyridoxamine) / NephroGenex
Preclinical, Journal: Repurposing pyridoxamine for therapeutic intervention of intravascular cell-cell interactions in mouse models of sickle cell disease. (Pubmed Central) - Nov 3, 2019
Studies using platelets and neutrophils from sickle cell disease mice and patients suggested that treatment with pyridoxamine reduced the activation state of platelets and neutrophils. These results suggest that pyridoxamine may be a novel therapeutic and a supplement to hydroxyurea to prevent and treat vaco-occlusion events in sickle cell disease.
- | Oral Pyridorin (pyridoxamine) / NephroGenex
Enrollment change, Trial termination: PIONEER: Pyridorin in Diabetic Nephropathy (clinicaltrials.gov) - Mar 9, 2016
P3, N=328, Terminated, Sponsor: NephroGenex, Inc.
These results suggest that pyridoxamine may be a novel therapeutic and a supplement to hydroxyurea to prevent and treat vaco-occlusion events in sickle cell disease. N=600 --> 328 | Recruiting --> Terminated
- |||||| Oral Pyridorin (pyridoxamine) / NephroGenex
Enrollment open: PIONEER: Pyridorin in Diabetic Nephropathy (clinicaltrials.gov) - Jun 17, 2014
P3, N=600, Recruiting, Sponsor: NephroGenex, Inc.
N=600 --> 328 | Recruiting --> Terminated Not yet recruiting --> Recruiting
- |||||||||| Oral Pyridorin (pyridoxamine) / NephroGenex
New P3 trial: PIONEER: Pyridorin in Diabetic Nephropathy (clinicaltrials.gov) - Jun 3, 2014
P3, N=600, Not yet recruiting, Sponsor: NephroGenex, Inc.
- |||| Oral Pyridorin (pyridoxamine) / NephroGenex
Trial completion: Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes (clinicaltrials.gov) - Aug 5, 2012
P2, N=317, Completed, Sponsor: NephroGenex, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed